Chemomab Therapeutics Ltd.
NASDAQ: CMMB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adi Mor George
- Employees
- 20
- Headquarters
- Tel Aviv, Israel
- IPO year
- 2019
- Market cap
- $9.5M
- Website
- https://www.chemomab.com
Loading CMMB…
Loading profile data…Frequently asked questions about CMMB
What does Chemomab Therapeutics Ltd. (CMMB) do?
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This pote...
Where does CMMB trade?
Chemomab Therapeutics Ltd. (CMMB) trades on the NASDAQ Capital Market.
What sector is CMMB in?
Chemomab Therapeutics Ltd. (CMMB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chemomab Therapeutics Ltd.?
Adi Mor George is the chief executive officer of Chemomab Therapeutics Ltd. (CMMB).
Where is Chemomab Therapeutics Ltd. headquartered?
Chemomab Therapeutics Ltd. is headquartered in Israel.
Does CMMB pay a dividend?
Chemomab Therapeutics Ltd. (CMMB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CMMB go public?
Chemomab Therapeutics Ltd. (CMMB) completed its initial public offering in 2019.
Is CMMB an ADR?
Yes — CMMB is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Chemomab Therapeutics Ltd. reporting and dividends follow the underlying issuer.